Stockwatch: Gilead, BMS Expose High Cost Of M&A
Financial Results Take The Shine Off Acquisitions
Executive Summary
Expensive acquisitions are in the spotlight during earnings season. The purchases of Kite and Celgene by Gilead and Bristol-Myers Squibb are not turning out to be what was written on the tin.